Paul Jeffrey

BusStim works with biotech startups to make them investment ready. We assist startups in preparing themselves to be introduced to our network of investors and pharma industry business development executives. BusStim works to understand the origins of startups and the value and potential commercialization of their intellectual property. We review the founders’ backgrounds and capabilities i to assess their needs and any gaps in their management team. We work to improve the management of early stage biotech companies. BusStim has placed Chief Executive Officers and Chief Medical Officers from our team of experts. We perform a rigorous due diligence process that includes scientific valuation, market analysis, and legal analysis. After we complete, we prepare an investors and pharma presentation which Includes: • Key POC preclinical studies completed or need to be conducted • Innovative and cost efficient clinical & regulatory plans/strategies • An enhanced management team We are always seeking new investor relationships. The risk sharing collaboration agreement services that we provide to our partner companies will make sure they are “Investment Ready”. BusStim’s partner companies will be better prepared for the funding raising campaign and Investors due diligence processes time and money. BusStim brings the following “Value-Add” to this pharma collaboration process: • Identification of opportunities to address unmet needs • De-risked assets that meet partners’ requirements • Prospective assets aligned with pharma’s portfolio needs • Translational research components aligned with human disease reduce risk and add value. • “BusStim is Bridging the Gap between Biotechs and Pharma”